biotech · Non small cell lung cancer · oligometastatic hormone sensitive prostate cancer · CERO
CERo Therapeutics
CERO THERAPEUTICS HOLDINGS, INC.
CERo Therapeutics is a biotech organization headquartered in South San Francisco, USA. It trades on NYSE under ticker CERO. Primary therapeutic focus areas include Non small cell lung cancer, oligometastatic hormone sens
201 Haskins Way, 230, South San Francisco, California 94080, US HQ
17 Employees
Public company Type
CERO · NYSE Ticker
Company details
- Status
- Public
- HQ
- 201 Haskins Way, 230, South San Francisco, California 94080, US
- Employees
- 17
- Programs
- 47
- Drugs
- 84
- Patents
- 14
IMFINZI 50 mg/mL concentrate for solution for infusion.
Phase 2 · small molecule · oligometastatic hormone sensitive prostate cancer
IMFINZI 50 mg/mL concentrate for solution for infusion. for oligometastatic hormone sensitive prostate cancer is a Phase 2 program (small_molecule) at CERO THERAPEUTICS HOLDINGS, INC. with 1 ClinicalTrials.gov record(s).
Internal code POSTCARD - GETUG-P13
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- CERO THERAPEUTICS HOLDINGS, INC.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- oligometastatic hormone sensitive prostate cancer
- Status
- active
- Trials
- 1